Travere Therapeutics Announces Completion of Public Offering of Common Stock and Pre-Funded Warrants and Exercise in Full of Underwriters’ Option to Purchase Additional Shares

SAN DIEGO , March 03, 2023 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the completion of its previously announced underwritten public offering of 9,703,750 shares of its common stock at a price to the public of $21.00 per share and pre-funded warrants to purchase 1,250,000 shares of its common stock at a price to the public of $20.9999 per pre-funded warrant, including 1,428,750 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares.

View Full Press Release